Literature DB >> 23980106

Relative contributions of lipooligosaccharide inner and outer core modifications to nontypeable Haemophilus influenzae pathogenesis.

Pau Morey1, Cristina Viadas, Begoña Euba, Derek W Hood, Montserrat Barberán, Carmen Gil, María Jesús Grilló, José Antonio Bengoechea, Junkal Garmendia.   

Abstract

Nontypeable Haemophilus influenzae (NTHi) is a frequent commensal of the human nasopharynx that causes opportunistic infection in immunocompromised individuals. Existing evidence associates lipooligosaccharide (LOS) with disease, but the specific and relative contributions of NTHi LOS modifications to virulence properties of the bacterium have not been comprehensively addressed. Using NTHi strain 375, an isolate for which the detailed LOS structure has been determined, we compared systematically a set of isogenic mutant strains expressing sequentially truncated LOS. The relative contributions of 2-keto-3-deoxyoctulosonic acid, the triheptose inner core, oligosaccharide extensions on heptoses I and III, phosphorylcholine, digalactose, and sialic acid to NTHi resistance to antimicrobial peptides (AMP), self-aggregation, biofilm formation, cultured human respiratory epithelial infection, and murine pulmonary infection were assessed. We show that opsX, lgtF, lpsA, lic1, and lic2A contribute to bacterial resistance to AMP; lic1 is related to NTHi self-aggregation; lgtF, lic1, and siaB are involved in biofilm growth; opsX and lgtF participate in epithelial infection; and opsX, lgtF, and lpsA contribute to lung infection. Depending on the phenotype, the involvement of these LOS modifications occurs at different extents, independently or having an additive effect in combination. We discuss the relative contribution of LOS epitopes to NTHi virulence and frame a range of pathogenic traits in the context of infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23980106      PMCID: PMC3811809          DOI: 10.1128/IAI.00492-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  67 in total

Review 1.  Agents that increase the permeability of the outer membrane.

Authors:  M Vaara
Journal:  Microbiol Rev       Date:  1992-09

2.  Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  A J Lesse; A A Campagnari; W E Bittner; M A Apicella
Journal:  J Immunol Methods       Date:  1990-01-24       Impact factor: 2.303

3.  Defined medium for growth of Haemophilus influenzae.

Authors:  R M Herriott; E Y Meyer; M Vogt; M Modan
Journal:  J Bacteriol       Date:  1970-02       Impact factor: 3.490

Review 4.  Peptides as weapons against microorganisms in the chemical defense system of vertebrates.

Authors:  P Nicolas; A Mor
Journal:  Annu Rev Microbiol       Date:  1995       Impact factor: 15.500

5.  Phosphorylcholine expression by nontypeable Haemophilus influenzae correlates with maturation of biofilm communities in vitro and in vivo.

Authors:  Wenzhou Hong; Bing Pang; Shayla West-Barnette; W Edward Swords
Journal:  J Bacteriol       Date:  2007-06-15       Impact factor: 3.490

6.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd.

Authors:  R D Fleischmann; M D Adams; O White; R A Clayton; E F Kirkness; A R Kerlavage; C J Bult; J F Tomb; B A Dougherty; J M Merrick
Journal:  Science       Date:  1995-07-28       Impact factor: 47.728

7.  Lipooligosaccharides containing phosphorylcholine delay pulmonary clearance of nontypeable Haemophilus influenzae.

Authors:  Bing Pang; Dana Winn; Ryan Johnson; Wenzhou Hong; Shayla West-Barnette; Nancy Kock; W Edward Swords
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

8.  Generation of lipooligosaccharide mutants of Haemophilus influenzae type b.

Authors:  R McLaughlin; S M Spinola; M A Apicella
Journal:  J Bacteriol       Date:  1992-10       Impact factor: 3.490

9.  The role of a repetitive DNA motif (5'-CAAT-3') in the variable expression of the Haemophilus influenzae lipopolysaccharide epitope alpha Gal(1-4)beta Gal.

Authors:  N J High; M E Deadman; E R Moxon
Journal:  Mol Microbiol       Date:  1993-09       Impact factor: 3.501

10.  Characterization and modeling of the Haemophilus influenzae core and supragenomes based on the complete genomic sequences of Rd and 12 clinical nontypeable strains.

Authors:  Justin S Hogg; Fen Z Hu; Benjamin Janto; Robert Boissy; Jay Hayes; Randy Keefe; J Christopher Post; Garth D Ehrlich
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  29 in total

1.  Incorporation of phosphorylcholine into the lipooligosaccharide of nontypeable Haemophilus influenzae does not correlate with the level of biofilm formation in vitro.

Authors:  Carmen Puig; Sara Marti; Peter W M Hermans; Marien I de Jonge; Carmen Ardanuy; Josefina Liñares; Jeroen D Langereis
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

Review 2.  What's on the Outside Matters: The Role of the Extracellular Polymeric Substance of Gram-negative Biofilms in Evading Host Immunity and as a Target for Therapeutic Intervention.

Authors:  John S Gunn; Lauren O Bakaletz; Daniel J Wozniak
Journal:  J Biol Chem       Date:  2016-04-21       Impact factor: 5.157

3.  Comparative Analyses of the Lipooligosaccharides from Nontypeable Haemophilus influenzae and Haemophilus haemolyticus Show Differences in Sialic Acid and Phosphorylcholine Modifications.

Authors:  Deborah M B Post; Margaret R Ketterer; Jeremy E Coffin; Lorri M Reinders; Robert S Munson; Thomas Bair; Timothy F Murphy; Eric D Foster; Bradford W Gibson; Michael A Apicella
Journal:  Infect Immun       Date:  2016-01-04       Impact factor: 3.441

Review 4.  On the in vivo significance of bacterial resistance to antimicrobial peptides.

Authors:  Margaret E Bauer; William M Shafer
Journal:  Biochim Biophys Acta       Date:  2015-02-18

5.  Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection.

Authors:  Begoña Euba; Javier Moleres; Cristina Viadas; Montserrat Barberán; Lucía Caballero; María-Jesús Grilló; José Antonio Bengoechea; Juan Pablo de-Torres; Josefina Liñares; José Leiva; Junkal Garmendia
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

6.  Binding of human factor H to outer membrane protein P5 of non-typeable Haemophilus influenzae contributes to complement resistance.

Authors:  Jeroen D Langereis; Marien I de Jonge; Jeffrey N Weiser
Journal:  Mol Microbiol       Date:  2014-08-18       Impact factor: 3.501

7.  Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae.

Authors:  Begoña Euba; Javier Moleres; Víctor Segura; Cristina Viadas; Pau Morey; David Moranta; José Leiva; Juan Pablo de-Torres; José Antonio Bengoechea; Junkal Garmendia
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

8.  Increased biofilm formation by nontypeable Haemophilus influenzae isolates from patients with invasive disease or otitis media versus strains recovered from cases of respiratory infections.

Authors:  Carmen Puig; Arnau Domenech; Junkal Garmendia; Jeroen D Langereis; Pascal Mayer; Laura Calatayud; Josefina Liñares; Carmen Ardanuy; Sara Marti
Journal:  Appl Environ Microbiol       Date:  2014-09-05       Impact factor: 4.792

9.  Host Antimicrobial Peptides in Bacterial Homeostasis and Pathogenesis of Disease.

Authors:  Derek R Heimlich; Alistair Harrison; Kevin M Mason
Journal:  Antibiotics (Basel)       Date:  2014-12-01

10.  Relative Contribution of P5 and Hap Surface Proteins to Nontypable Haemophilus influenzae Interplay with the Host Upper and Lower Airways.

Authors:  Begoña Euba; Javier Moleres; Cristina Viadas; Igor Ruiz de los Mozos; Jaione Valle; José Antonio Bengoechea; Junkal Garmendia
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.